The Technical Analyst
Eagle Pharmaceuticals Inc [EGRX]
Exchange: NASDAQ Sector: Healthcare Industry: Drug Manufacturers—Specialty & Generic
Eagle Pharmaceuticals Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
-6.40% $4.39
America/New_York / 17 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 57.01 mill |
| EPS: | 0.850 |
| P/E: | 5.16 |
| Earnings Date: | May 06, 2024 |
| SharesOutstanding: | 12.99 mill |
| Avg Daily Volume: | 0.213 mill |
| RATING 2024-04-17 |
|---|
| A |
| Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Neutral | |
| Return On Asset: | Buy | |
| DE: | Buy | |
| P/E: | Buy | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 1/22 | 2/22 | 3/22 | 4/22 | 1/23 | 2/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE 5.16 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0.11x |
| Company: PE 5.16 | industry: PE 47.78 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 3.98 - 4.80 ( +/- 9.27%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-02-28 | Tarriff Scott | Sell | 2 119 | Common Stock |
| 2024-02-27 | Cahill Brian Joseph | Buy | 3 800 | Common Stock |
| 2024-02-27 | Cahill Brian Joseph | Sell | 1 589 | Common Stock |
| 2024-02-27 | Tarriff Scott | Buy | 12 950 | Common Stock |
| 2024-02-27 | Tarriff Scott | Sell | 3 154 | Common Stock |
| INSIDER POWER |
|---|
| 59.21 |
| Last 99 transactions |
| Buy: 818 589 | Sell: 362 958 |
Forecast:
16:00 - $4.38
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $4.38
Forecast 2: 16:00 - $4.38
Forecast 3: 16:00 - $4.38
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $4.39 (-6.40% ) |
| Volume | 0.109 mill |
| Avg. Vol. | 0.213 mill |
| % of Avg. Vol | 51.22 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For EGRX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:34 | sell | $5.21 | N/A | Active |
|---|
EGRX
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.
Latest Press Releases
2024-04-15 07:00:00 - Press Release
Eagle Pharmaceuticals To Present Additional Data From Phase Iii Trial Demonstrating Sustained Response Of Amisulpride For The Rescue Treatment Of Postoperative Nausea And Vomiting (ponv) At The Upcoming Aspan 2024 National Conference In Orlando, Florida
-- single dose, iv amisulpride (10 mg) results in sustained antiemetic effect with supratherapeutic plasma levels of drug being maintained for at least 24 hours in patients requiring ponv rescue versus placebo -- -- single dose, iv amisulpride (10 mg) results in sustained antiemetic effect with supratherapeutic plasma levels of drug being maintained for at least 24 hours in patients requiring ponv rescue versus placebo --
2024-04-12 16:05:00 - Press Release
Eagle Pharmaceuticals Announces Receipt Of Notification Of Deficiency From Nasdaq Regarding Requirement To Timely File Annual Report On form 10-k
Woodcliff lake, n.j., april 12, 2024 (globe newswire) -- eagle pharmaceuticals, inc. (nasdaq: egrx) (the “company”) today announced that it received a notice (the “notice”) on april 8, 2024 from the listing qualifications department of the nasdaq stock market llc (“nasdaq”) advising the company that due to the company's failure to timely file its annual report on form 10-k for the fiscal year ended december 31, 2023 (the “form 10-k”), with the securities and exchange commission (the “sec”), the company is not in compliance with nasdaq's continued listing requirements under nasdaq listing rule 5250(c)(1) (the “rule”), which requires the timely filing of all required periodic reports with the sec.
2024-02-09 12:15:00 - Press Release
Shareholders Of Eagle Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before February 9, 2024 To Discuss Your Rights - Egrx
New york, ny / accesswire / february 9, 2024 / if you suffered a loss on your eagle pharmaceuticals, inc. (nasdaq:egrx) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/eagle-pharmaceuticals-inc-lawsuit-submission-form?prid=66577&wire=1 or contact joseph e. levi, esq.
2024-02-09 12:00:00 - Press Release
Eagle Pharmaceuticals Shareholder Action Reminder: Securities Litigation Partner James (josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Eagle Pharmaceuticals To Contact Him Directly To Discuss Their Options
If you suffered losses exceeding $100,000 investing in eagle pharmaceuticals stock or options between august 8, 2023 and november 28, 2023 and would like to discuss your legal rights, call faruqi & faruqi partner josh wilson directly at 877-247-4292 or 212-983-9330 (ext. 1310). you may also click here for additional information: www.faruqilaw.com/egrx.
2024-02-09 11:30:00 - Press Release
Levi & Korsinsky Reminds Eagle Pharmaceuticals, Inc. Investors Of The Pending Class Action Lawsuit With A Lead Plaintiff Deadline Of February 9, 2024 - Egrx
New york, ny / accesswire / february 9, 2024 / if you suffered a loss on your eagle pharmaceuticals, inc. (nasdaq:egrx) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/eagle-pharmaceuticals-inc-lawsuit-submission-form?prid=66572&wire=1 or contact joseph e. levi, esq.
Latest News
2023-12-06 16:05:00 - GlobeNewsWire
Eagle Pharmaceuticals to Present Abstract on Post-hoc Analysis of Amisulpride at the 77th PGA (PostGraduate Assembly in Anesthesiology) in New York City
-- BARHEMSYS® (amisulpride) Injection is the first and only antiemetic approved by the U.S. Food and Drug Administration (“FDA”) for rescue treatment of postoperative nausea and vomiting (“PONV”) despite prophylaxis1 and is also approved for the treatment of PONV in patients who have not received prophylaxis and for the prevention of PONV -- -- In patients who experience PONV, the incidence of nausea is substantially greater than the incidence of vomiting2 , 3 --
2023-11-27 11:19:35 - Zacks Investment Research
Down -33.75% in 4 Weeks, Here's Why Eagle Pharmaceuticals (EGRX) Looks Ripe for a Turnaround
Eagle Pharmaceuticals (EGRX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
2023-11-10 11:17:13 - Zacks Investment Research
Down -26.73% in 4 Weeks, Here's Why Eagle Pharmaceuticals (EGRX) Looks Ripe for a Turnaround
The heavy selling pressure might have exhausted for Eagle Pharmaceuticals (EGRX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
2023-11-09 07:30:00 - GlobeNewsWire
Eagle Delays Third Quarter 2023 Results and Conference Call
WOODCLIFF LAKE, N.J., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that it will be delaying the release of its third quarter 2023 results and investor conference call, previously scheduled for today, Thursday, November 9, 2023. The Company currently anticipates filing a Form 12b-25, Notification of Late Filing, with the Securities and Exchange Commission no later than one business day after the due date of its Quarterly Report on Form 10-Q for the third quarter ended September 30, 2023 (the “Form 10-Q"), and expects to file its Form 10-Q by November 14, 2023, prior to the expiration of the extension period provided by Rule 12b-25 under the Securities Exchange Act of 1934.
2023-11-08 08:30:00 - GlobeNewsWire
Eagle Pharmaceuticals to Host Third Quarter 2023 Financial Results on November 9, 2023
WOODCLIFF LAKE, N.J., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its third quarter 2023 financial results on Thursday, November 9, 2023, before the market opens.
2023-09-29 09:46:10 - Zacks Investment Research
4 Undervalued Medical Stocks to Buy Amid High Market Volatility
Amid volatility, undervalued companies with solid prospects cushion investors from market jitters, while their robust fundamentals ensure higher returns. ACHC, PGNY, EGRX and NRBO are four such stocks.
2023-09-19 16:05:00 - GlobeNewsWire
Eagle Pharmaceuticals to Present at the Cantor Global Healthcare Conference 2023
WOODCLIFF LAKE, N.J., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Scott Tarriff, Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will participate in a panel presentation at the Cantor Global Healthcare Conference 2023 as follows:
2023-09-11 06:50:00 - GlobeNewsWire
Eagle Pharmaceuticals to Present CAL02 Trial in Progress at the 2023 ASM/ESCMID Joint Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance
-- CAL02 is a unique therapeutic agent that is designed to work differently from antibiotics, aiming to disarm an infectious pathogen's virulence factors to reduce damage and mitigate disease ---- The first-in-human study showed positive safety and efficacy when added to standard of care in patients with severe community-acquired bacterial pneumonia -- WOODCLIFF LAKE, N.J., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that its abstract describing the global in-progress Phase 2 study of CAL02, a first-in-class, broad-spectrum, anti-virulence agent under development as an adjunct to antibiotic therapy for the treatment of severe community-acquired bacterial pneumonia (“SCABP”), has been selected for a poster presentation at the conference co-sponsored by the American Society for Microbiology (“ASM”) and the European Society for Clinical Microbiology and Infectious Diseases (“ESCMID”)...
2023-08-30 06:50:00 - GlobeNewsWire
Eagle Pharmaceuticals to Present BYFAVO® (remimazolam) for Injection Abstract at Prestigious Society for Neuroscience in Anesthesiology and Critical Care (SNACC) Conference
-- Abstract compares relative effects on cognitive function following sedation with Byfavo (remimazolam) for injection versus midazolam -- Abstract compares relative effects on cognitive function following sedation with Byfavo (remimazolam) for injection versus midazolam
2023-08-22 16:05:00 - GlobeNewsWire
Eagle Pharmaceuticals to Present at Two Upcoming Healthcare Conferences
WOODCLIFF LAKE, N.J., Aug. 22, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Scott Tarriff, Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will present at the following healthcare conferences: